A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
NCT ID: NCT00294736
Last Updated: 2012-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
57 participants
INTERVENTIONAL
2005-11-30
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Part I will establish the maximum tolerated dose (MTD) of Tarceva in current smokers.
In Part II, patients will be randomized 1:1 to two treatment groups: Arm A (Tarceva MTD established in Part I) and Arm B (150 mg Tarceva daily). Patients in both arms will be treated for two weeks and then have pharmacokinetic samples collected on day 14. Part II is open as of Nov-2006.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Arm A (Tarceva MTD established in Part I)
Tarceva
Dose Escalation: 150-350+ mg/day
Arm B
Arm B (150 mg Tarceva daily).
Tarceva
Dose Escalation: 150-350+ mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tarceva
Dose Escalation: 150-350+ mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have received 1 or 2 prior chemotherapy regimens for advanced NSCLC and now have progressive disease;
* Must have recovered from any treatment-related toxicities prior to registration, except for alopecia, grade 1 fatigue, or grade 1 neurotoxicity;
* A current cigarette smoker (minimum of 10 cigarettes per day for \>= 1 year and have a positive test for cotinine) despite advice and support to quit;
* Age \>= 18 years;
* ECOG PS 0-1 and predicted life expectancy \>= 12 weeks;
* Previous surgery is permitted provided that wound healing has occurred prior to registration;
* Adequate hematopoietic, hepatic and renal function defined as follows: ANC \>= 1.5 x 10\^9/L, platelets \>= 100 x 10\^9/L, bilirubin \<= 1.5 x ULN, ALT \<= 2.5 x ULN (or 5 x ULN in case of liver metastases), creatinine \<= 1.5 x ULN;
* No prior treatment with Tarceva or gefitinib (or other drug with significant activity against EGFR (eg, cetuximab and/or ZD6474));
* Patients with reproductive potential must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test within 14 days prior to registration;
* Accessible for repeat dosing and follow-up.
Exclusion Criteria
* Concomitant CYP3A4 or CYP1A2 inducers/inhibitors (or during 14 days prior to study) with the exception of tobacco;
* Other active malignancies, unless disease-free and without cancer-specific therapy for at least the last 5 years. Basal or squamous cell skin cancers are not excluded;
* Significant history of cardiac disease unless the disease is well-controlled;
* Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study;
* History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements; of the study or to provide informed consent.
* Gastrointestinal abnormalities, including inability to take oral medication, requirement for IV alimentation, active peptic ulcer or prior surgical procedures affecting absorption;
* Clinically significant ophthalmologic abnormalities;
* Pregnant or breast-feeding females. Males or females not practicing effective birth control;
* Symptomatic brain metastases which are not stable, require steroids, or that have required radiation within the last 28 days;
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug;
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OSI Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
OSI Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
University of Edinburgh,Division of Oncology,
Edinburgh, Scotland, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
Ninewells Hospital
Dundee, , United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, , United Kingdom
Sir Bobby Robson Cancer Trials Research Centre
Newcastle upon Tyne, , United Kingdom
Department of Oncology
Sheffield, , United Kingdom
Royal Marsden Hospital
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-003883-46
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
OSI-774-107
Identifier Type: -
Identifier Source: org_study_id